Article Text

Download PDFPDF
1161 Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in patients with ovarian cancer: a systematic review
  1. Cristina Taliento1,
  2. Stefano Restaino2,
  3. Gennaro Scutiero3,
  4. Martina Arcieri4,
  5. Giulia Bernardi5,
  6. Ruby Martinello6,
  7. Lorenza Driul7,
  8. Anna Myriam Perrone8,
  9. Anna Fagotti9,
  10. Giovanni Scambia10,
  11. Pantaleo Greco5 and
  12. Giuseppe Vizzielli11
  1. 1Department of Medical Sciences, Ferrara, Italy
  2. 2Institute of Obstetrics and Gynecology, Ferrara, Italy
  3. 3University of Ferrara, Ferrara, Italy
  4. 4Italy, Udine, Italy
  5. 5Clinic of Obstetrics and Gynecology, Ferrara, Italy
  6. 6Ferrara, Italy
  7. 7Department of Medical Sciences, Udine, Italy
  8. 8Institute of Obstetrics and Gynecology, Bologna, Italy
  9. 9University of Ferrara, Roma, Italy
  10. 10Italy, Roma, Italy
  11. 11Udine, Italy


Introduction/Background PIPAC consists in delivering normothermic chemotherapy solution directly into the peritoneal cavity as an aerosol under pressure. Currently PIPAC is considered as a palliative treatment for patients suffering from non-resectable peritoneal carcinomatosis. We performed a SR to assess tolerance and response of this novel method among patient with OC.

Methodology We searched electronic database PubMed, Embase, Web of Science, Clinical We only included clinical studies reporting PIPAC with cisplatin and doxorubicin in patients with ovarian cancer.

Results This systematic review included 4 studies. In 3 studies all patients were pretreated with cytoreductive surgery, in 1 study surgery was performed in 8/34 (23%) patients. Mean PCI at first PIPAC procedure ranged from 16.3 to 19.6. All studies reported the proportion of patients with ascites at the first PIPAC with a pooled rate of 48,3%. Pooled rate of CTCAE Grade 3 toxicity calculated on the total number of PIPAC was 6% and Grade 4 was 0.9%. One study reported two cases of small bowel perforation related or potentially related to PIPAC. On study reported a cumulative survival after 400 days of 62% and a mean actuarial survival time of all patients who underwent PIPAC of 442 days. In another study the mean time to progression was 144 days (95% CI 122–168 days).

Conclusion This systematic review demonstrated that PIPAC with cisplatin and doxorubicin appear to have a good safety profile with low toxicity and encouraging trend in terms of overall survival.

Disclosures No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.